<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PSA Rising Prostate Cancer Blog &#187; Add new tag</title>
	<atom:link href="http://www.psa-rising.com/blog/tag/add-new-tag/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.psa-rising.com/blog</link>
	<description></description>
	<lastBuildDate>Tue, 16 Aug 2011 09:39:00 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>Provenge available for men with advanced prostate cancer at Roswell Park</title>
		<link>http://www.psa-rising.com/blog/2011/02/provenge-available-for-men-with-advanced-pca-at-roswell-park/</link>
		<comments>http://www.psa-rising.com/blog/2011/02/provenge-available-for-men-with-advanced-pca-at-roswell-park/#comments</comments>
		<pubDate>Wed, 16 Feb 2011 00:39:59 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Hormone refractory]]></category>
		<category><![CDATA[Immunotherapy]]></category>
		<category><![CDATA[Metastatic]]></category>
		<category><![CDATA[PCa Treatments]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[Add new tag]]></category>
		<category><![CDATA[Advanced PCa]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=2368</guid>
		<description><![CDATA[February 7 2011, BUFFALO, NY — The nation’s first FDA-approved cancer treatment vaccine, Provenge (sipuleucel-T), is being offered for the first time in Western New York at Roswell Park Cancer Institute (RPCI). The vaccine is designed for men with advanced prostate cancer who have limited treatment options and who meet eligibility requirements. “It’s the first [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2011/02/provenge-available-for-men-with-advanced-pca-at-roswell-park/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Investor Interviews Hy Levitsky M.D. on Provenge</title>
		<link>http://www.psa-rising.com/blog/2009/04/investorv-interview-with-hy-levitsky/</link>
		<comments>http://www.psa-rising.com/blog/2009/04/investorv-interview-with-hy-levitsky/#comments</comments>
		<pubDate>Thu, 23 Apr 2009 03:50:15 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Biotech companies]]></category>
		<category><![CDATA[Cancer Treatments]]></category>
		<category><![CDATA[Dendreon]]></category>
		<category><![CDATA[Immunotherapy]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[trial results]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[Add new tag]]></category>
		<category><![CDATA[Dendreon IV board]]></category>
		<category><![CDATA[HY Levitsky M.D.]]></category>
		<category><![CDATA[rufustoehee]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=1177</guid>
		<description><![CDATA[A four part interview with  Hy Levitsky M.D., professor of oncology and tumor immunology at Johns Hopkins Medical School and co-inventor GVAX anti-cancer vaccine, is posted on Dendreon Investor Village website. Interview conducted by rufustoehee, a dentist and Dendreon investor, published 4/22/2009. By way of introduction, Dr Levitsky&#8217;s bio is posted alphabetically downpage among those [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/04/investorv-interview-with-hy-levitsky/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

